Role of the Duration of Fondaparinux (Arixtra~R) Prophylaxis in Preventing Venous Thromboembolism Following Major Orthopaedic Surgery

摘要

Fondaparinux (Arixtra~R) is a synthetic and selective factor Xa inhibitor which reduced by more than 50% the incidence of venous thromboembolism compared to enoxaparin in four randomized trials in major orthopaedic surgery with a similar safety profile regarding clinically relevant bleeding. Both treatments were administered up to day 11 after -surgery. Using logistic regression analyses, we show that the efficacy of both fondaparinux and enoxaparin in preventing venous thromboembolism was significantly increased by longer treatment duration (p<0.001). However, for similar treatment durations, the superior efficacy of fondaparinux over enoxaparin was maintained.